2213 Tumor suppressors p53 and ARF control oncogenic potential of triple-negative breast cancer cells by regulating RNA editing enzyme ADAR1
OBJECTIVES/SPECIFIC AIMS: Triple-negative breast cancer (TNBC) accounts for one-fifth of the breast cancer patient population. The heterogeneous nature of TNBC and lack of options for targeted therapy make its treatment a constant adventure. The deficiency of tumor suppressors p53 and ARF is one of...
Main Authors: | Che-Pei Kung, Emily A. Bross, Catherine E. Kuzmicki, Michael Benjamin, Leonard B. Maggi, Jason D. Weber |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2018-06-01
|
Series: | Journal of Clinical and Translational Science |
Online Access: | https://www.cambridge.org/core/product/identifier/S2059866118001437/type/journal_article |
Similar Items
-
3174 Tumor suppressors p53 and ARF control oncogenic potential of triple-negative breast cancer cells by regulating RNA editing enzyme ADAR1
by: Che-Pei Kung, et al.
Published: (2019-03-01) -
ARF and p53 Coordinate Tumor Suppression of an Oncogenic IFN-β-STAT1-ISG15 Signaling Axis
by: Jason T. Forys, et al.
Published: (2014-04-01) -
RNA editing enzyme ADAR1 is required for early T cell development
Published: (2021-07-01) -
RNA editing enzyme ADAR1 is required for early T cell development
by: Richard Xufeng, et al.
Published: (2020-01-01) -
The RNA-Editing Enzyme ADAR1 Controls Innate Immune Responses to RNA.
by: Mannion, N, et al.
Published: (2014)